SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals’ arm launches Milnacipran Hydrochloride tablets

19 Mar 2026 Evaluate

Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has launched Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. Glenmark’s Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.

According to IQVIA sales data for the 12-month period ending January 2026, the Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg market achieved annual sales of around $102.9 million.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma. Share Price

2292.75 27.50 (1.21%)
10-Jul-2026 13:07 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1931.15
Dr. Reddys Labs. 1243.60
Cipla 1441.60
Zydus Lifesciences 1148.30
Lupin 2500.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: